Cost-utility analysis of inotuzumab ozogamicin for relapsed or refractory B cell acute lymphoblastic leukemia from the perspective of Taiwan's health care system.
Tsung-Ying LeeHsuan-Ying ChenTsai-Yun ChenSin-Syue LiWei-Tse FangYao-Chun WenYu-Wen LoHuang-Tz OuPublished in: The European journal of health economics : HEPAC : health economics in prevention and care (2020)
INO versus SOC has higher costs but is more effective. The use of INO is favorable for patients in the early treatment course and when more future benefit associated with INO is considered.